NMTC (NMTC) director sells 10,000 shares, retains 20,692 after trade

Rhea-AI Filing Summary

NEUROONE MEDICAL TECHNOLOGIES Corp Market Development Director Mark Christianson reported an open-market sale of 10,000 shares of Common Stock at an average price of $3.1773 per share. After this transaction, he directly holds 20,692 shares, indicating he retained a substantial remaining equity position in the company.

Insights

Insider trading analyst

Director sold 10,000 shares but kept a meaningful remaining stake.

Market Development Director Mark Christianson executed an open-market sale of 10,000 shares of NEUROONE MEDICAL TECHNOLOGIES Corp Common Stock at an average price of $3.1773 per share. This is a straightforward disposition coded as an open-market or private transaction.

Following the sale, Christianson directly owns 20,692 shares. Based on the visible data, the transaction appears as a partial reduction rather than a full exit from his position. The filing does not list any remaining derivative securities, so the disclosed stake consists of common shares only.

The Form 4 reflects a net-sell activity of 10,000 shares on June 30, 2026. Future company filings may provide additional context around any subsequent trades or changes in his ownership level.

Insider Trade Summary

Net Seller: 10,000 shares

Net Sell 1 txn

Insider Christianson Mark

Role Market Development Director

Sold 10,000 shs ($32K)

Type	Security	Shares	Price	Value
Sale	Common Stock	10,000	$3.1773	$32K

Holdings After Transaction: Common Stock — 20,692 shares (Direct)

Key Figures

Shares sold: 10,000 shares Sale price: $3.1773 per share Shares held after transaction: 20,692 shares +1 more

4 metrics

Shares sold 10,000 shares Open-market sale on June 30, 2026

Sale price $3.1773 per share Average price for the 10,000 shares sold

Shares held after transaction 20,692 shares Direct ownership following the sale

Net share change -10,000 shares Net-sell direction in transaction summary

Key Terms

open-market sale, Common Stock, Form 4, non-derivative

4 terms

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

""security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

non-derivative financial

""transaction_type": "non-derivative""

FAQ

What insider transaction did NMTC executive Mark Christianson report?

Mark Christianson reported an open-market sale of 10,000 shares of NEUROONE MEDICAL TECHNOLOGIES Corp Common Stock. The shares were sold at an average price of $3.1773 per share, according to the Form 4 insider trading report.

At what price did NMTC insider Mark Christianson sell his shares?

He sold 10,000 NMTC Common Stock shares at an average price of $3.1773 per share. This price reflects the weighted average for the open-market transaction disclosed in the Form 4 filing.

How many NEUROONE MEDICAL TECHNOLOGIES (NMTC) shares does Mark Christianson hold after the sale?

After the transaction, Mark Christianson directly holds 20,692 shares of NEUROONE MEDICAL TECHNOLOGIES Corp Common Stock. This remaining position shows he continues to have a meaningful equity stake in the company following the reported sale.

Was the NMTC insider transaction a buy or a sell by Mark Christianson?

The transaction was a sell. Form 4 data show a code “S” and identify it as an open-market sale, with 10,000 NMTC Common Stock shares disposed of by Market Development Director Mark Christianson on June 30, 2026.

Does the NMTC Form 4 show any derivative securities for Mark Christianson?

The Form 4 summary indicates no derivative transactions or remaining derivative positions for Mark Christianson. The reported activity involves only non-derivative Common Stock, focusing on a single open-market sale of 10,000 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/02/2026 - 04:40 PM Accepted by SEC EDGAR 07/02/2026 - 04:39 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Christianson Mark

(Last) (First) (Middle)

7599 ANAGRAM DR.

(Street)

EDEN PRAIRIE MINNESOTA 55344

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEUROONE MEDICAL TECHNOLOGIES Corp [ NMTC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Market Development Director

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/30/2026		S		10,000	D	$3.1773	20,692	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Emily Johns, by Power of Attorney	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)